Mesoblast
Market Cap
AU$1.8b
Last Updated
2020/10/29 10:47 UTC
Data Sources
Company Financials +
Executive Summary
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. More Details
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with adequate balance sheet.
Similar Companies
Share Price & News
How has Mesoblast's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MSB's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-1.3%
MSB
-1.2%
AU Biotechs
-2.4%
AU Market
1 Year Return
76.5%
MSB
14.2%
AU Biotechs
-8.3%
AU Market
Return vs Industry: MSB exceeded the Australian Biotechs industry which returned 12.6% over the past year.
Return vs Market: MSB exceeded the Australian Market which returned -8.9% over the past year.
Shareholder returns
| MSB | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.3% | -1.2% | -2.4% |
| 30 Day | -39.3% | -1.4% | 1.8% |
| 90 Day | -16.7% | 6.6% | 1.7% |
| 1 Year | 76.5%76.5% | 15.3%14.2% | -5.0%-8.3% |
| 3 Year | 131.6%131.6% | 115.6%108.5% | 14.6%-0.08% |
| 5 Year | -6.7%-7.6% | 215.8%197.2% | 41.6%12.1% |
Price Volatility Vs. Market
How volatile is Mesoblast's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Auditors Are Concerned About Mesoblast (ASX:MSB)2 months ago | Simply Wall St
Analysts Expect Breakeven For Mesoblast Limited (ASX:MSB)3 months ago | Simply Wall St
Have Insiders Been Buying Mesoblast Limited (ASX:MSB) Shares This Year?Valuation
Is Mesoblast undervalued compared to its fair value and its price relative to the market?
2.35x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MSB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MSB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MSB is unprofitable, so we can't compare its PE Ratio to the XX Biotechs industry average.
PE vs Market: MSB is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MSB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MSB is good value based on its PB Ratio (2.3x) compared to the AU Biotechs industry average (5.4x).
Next Steps
Future Growth
How is Mesoblast forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
64.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MSB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: MSB is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MSB's is expected to become profitable in the next 3 years.
Revenue vs Market: MSB's revenue (42% per year) is forecast to grow faster than the Australian market (4.6% per year).
High Growth Revenue: MSB's revenue (42% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MSB is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Mesoblast performed over the past 5 years?
-5.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MSB is currently unprofitable.
Growing Profit Margin: MSB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MSB is unprofitable, and losses have increased over the past 5 years at a rate of 5.9% per year.
Accelerating Growth: Unable to compare MSB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MSB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.7%).
Return on Equity
High ROE: MSB has a negative Return on Equity (-14.19%), as it is currently unprofitable.
Next Steps
Financial Health
How is Mesoblast's financial position?
Financial Position Analysis
Short Term Liabilities: MSB's short term assets ($136.5M) exceed its short term liabilities ($90.1M).
Long Term Liabilities: MSB's short term assets ($136.5M) exceed its long term liabilities ($94.1M).
Debt to Equity History and Analysis
Debt Level: MSB's debt to equity ratio (16.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if MSB's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MSB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MSB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Mesoblast current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MSB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MSB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MSB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MSB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MSB's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
7.1yrs
Average management tenure
CEO
Silviu Itescu (63 yo)
9.75yrs
Tenure
US$2,651,592
Compensation
Prof. Silviu Itescu, MBBS (Hons), FRACP, FACP, FACRA, FTSE has been the Chief Executive Officer and Managing Director of Mesoblast Limited since 2011. Prof. Itescu is the Chief Executive Officer at Mesobla ...
CEO Compensation Analysis
Compensation vs Market: Silviu's total compensation ($USD1.31M) is about average for companies of similar size in the Australian market ($USD1.33M).
Compensation vs Earnings: Silviu's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 9.75yrs | US$2.65m | 11.74% $ 212.3m | |
| Chief Financial Officer | 2.42yrs | US$1.27m | no data | |
| General Counsel & Corporate Executive | 9.25yrs | no data | no data | |
| Head of Pharma Partnering | no data | no data | no data | |
| Senior Vice President of Commercial | no data | no data | no data | |
| Chief Medical Officer | 1.17yrs | no data | no data | |
| Chief Operating Officer | 0.25yr | no data | no data | |
| Head of Corporate Finance & Strategy | no data | no data | no data | |
| Global Head of Corporate Communications | no data | no data | no data | |
| Head of Spinal Orthopedic Disorders | 5yrs | no data | no data | |
| Head of Research & New Product Development | 9.75yrs | no data | no data | |
| Head of Manufacturing | 9.75yrs | no data | no data |
7.1yrs
Average Tenure
58.5yo
Average Age
Experienced Management: MSB's management team is seasoned and experienced (7.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 9.75yrs | US$2.65m | 11.74% $ 212.3m | |
| Independent Non Executive Director | 7.5yrs | US$190.75k | no data | |
| Independent Non-Executive Chairman | 1.5yrs | US$546.28k | no data | |
| Independent Non-Executive Vice Chairman | 4.75yrs | US$247.50k | 0.011% $ 195.2k | |
| Independent Non-Executive Director | 16.08yrs | US$196.53k | 0.21% $ 3.8m | |
| Independent Non-Executive Director | 16.08yrs | US$196.53k | 0.18% $ 3.3m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 2.25yrs | US$171.74k | no data |
6.1yrs
Average Tenure
67yo
Average Age
Experienced Board: MSB's board of directors are considered experienced (6.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.4%.
Top Shareholders
Company Information
Mesoblast Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Mesoblast Limited
- Ticker: MSB
- Exchange: ASX
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$1.808b
- Shares outstanding: 583.09m
- Website: https://www.mesoblast.com
Number of Employees
Location
- Mesoblast Limited
- 55 Collins Street
- Level 38
- Melbourne
- Victoria
- 3000
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| LWB | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Dec 2004 |
| MSB | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Dec 2004 |
| MEOB.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Dec 2004 |
| MSB | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Dec 2004 |
| MESO | NasdaqGS (Nasdaq Global Select) | SPON ADR EACH REP 5 SHS | US | USD | Dec 2005 | |
| LWBA | DB (Deutsche Boerse AG) | SPON ADR EACH REP 5 SHS | DE | EUR | Dec 2005 |
Biography
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, h ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/29 10:47 |
| End of Day Share Price | 2020/10/29 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.